Questions to ask your doctor about the HHS peptide draft

You can start with: “I read about the HHS draft involving six peptide substances. Does any of it change the options appropriate for my health concern?” Bring the actual document rather than a screenshot claiming six FDA approvals. The Federal Register notice calls it a draft and schedules publication October 30, 2026; this guide was prepared October 28.

That framing gives the clinician a specific question without assuming the policy is final or that you need one of the listed substances. Ask what is currently known and which parts of an access claim would need confirmation by the dispensing pharmacy.

Describe symptoms, their duration, prior diagnoses, and what you hope will improve. A goal such as “recover faster” can refer to many conditions with different treatment choices. Ask whether further examination or testing is needed before discussing a medication.

Then ask about established alternatives and the reasons for considering any less-established approach. A useful answer explains what outcome matters, how it would be measured, and what would lead the clinician to reconsider the plan. The policy’s existence does not diagnose an injury, establish a cause of fatigue, or demonstrate that a particular peptide addresses your situation.

Ask whether the relevant evidence involves humans with your condition, the same molecule, the same route, and a comparable preparation. Separate studies of a parent protein, animal model, or analogue from studies of the actual proposed treatment. Ask which important risks and long-term outcomes remain uncertain.

The HHS draft specifies exact identities and routes, including Semax free base for intranasal use and KPV acetate for topical or oral forms. Those limits do not themselves prove clinical benefit. The FDA compounding explanation also makes clear that compounded drugs are not FDA-approved. A clinician should be able to discuss both the policy and the separate evidence question.

Bring current prescriptions, over-the-counter medicines, supplements, allergies, previous reactions, relevant diagnoses, and pregnancy or breastfeeding information when applicable. Include products obtained outside ordinary pharmacy care. Omitting a substance because it was sold as research material makes the medication history less useful.

The HHS telehealth preparation guide can help organize records and questions before an online visit. Ask how the clinician evaluates possible interactions and whether any specialist should be involved. Do not discontinue an existing prescription on your own to make room for a proposed peptide; treatment changes belong in the clinical discussion.

Ask who will dispense the medication, how to reach the pharmacist, and who answers clinical questions after the visit. Request clear instructions about follow-up timing, what progress will be assessed, and what symptoms should prompt contact or urgent care. A sales representative should not be your only route to medical advice.

Also ask how problems with packaging, labeling, or the preparation are reported. The draft includes product-quality and serious-adverse-event reporting conditions, but those proposed requirements do not replace a patient’s need for an accessible care team. Confirm costs and cancellation terms separately, so uncertainty about billing does not become a barrier to asking for help.